P
Pentixapharm
Biotech & Life Sciences · Berlin, Germany · Founded 2019 · IPO 2024
Improving the life of patients with malignant diseases through targeted molecular diagnostic and therapy based on innovative nuclear medicine MoreLess
Pentixapharm, established in 2019 and headquartered in Germany, specializes in the development of radiopharmaceuticals focusing on CXCR4 ligand-based approaches. The company targets both diagnostic and therapeutic applications across a range of hematological and solid cancers, as well as cardiovascular, endocrine, and inflammatory diseases. By utilizing a theranostic mode of action, Pentixapharm's solutions enable specific binding of ligands to pathological cell structures, facilitating both diagnosis and therapy. The business model revolves around the development and commercialization of these radiopharmaceuticals, with revenue generated through partnerships, licensing, and direct sales. Pentixapharm recently completed a successful spin-off from the Eckert Ziegler Group, culminating in its listing on the Frankfurt Stock Exchange. The company serves healthcare providers and research institutions, operating within the radiopharmaceutical sector. Key opportunities for investors include the company's innovative pipeline and its strategic positioning in the growing market for targeted cancer therapies. Keywords: radiopharmaceuticals, CXCR4 ligands, theranostic, cancer, diagnostics, therapeutics, IPO, Frankfurt Stock Exchange, healthcare, Germany.
Company overview
Pentixapharm company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2019
- Headquarters
- Berlin, Germany
- Employees
- 37
- Open positions
- 2
- Dealroom signal
- 59.4
Valuation & funding
Pentixapharm funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | Jul 2026 | $22M | — | Undisclosed | ↗ |
| IPO✓Exit | Oct 2024 | $0 | — | Undisclosed | — |
| SERIES A✓Equity / VC | Feb 2020 | $17M | $66M | Eckert Life Science Accelerator | ↗ |
| CORPORATE SPINOUT✓Other financing | Jun 2019 | $0 | — | Eckert & Ziegler Bebig SA | ↗ |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
Growth signals
Pentixapharm website traffic
Latest recorded traffic for Pentixapharm is 2.1K monthly website visits, up 5% over the last three months. Pentixapharm's team declined 26% over the past year.
Hiring
Open positions at Pentixapharm
Current openings linked to this company in Dealroom.
Comparisons
Pentixapharm compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Pentixapharm's talent
Source: Dealroom Talent Intelligence.
Investors
2 investors on Pentixapharm's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Pentixapharm has talent and traffic
team presence
In the news
Latest news about Pentixapharm
Recent press, funding announcements, and product moves mentioning Pentixapharm — open to read from the original sources.
Market sentiment
What the market is saying about Pentixapharm
An AI-synthesized read of the highest-engagement posts about Pentixapharm on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Pentixapharm’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.